BLAIV (INFUSION)INJECTABLEPriority Review
Approved
Dec 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
Priority Review
RAXIBACUMAB (raxibacumab) by GSK is anthrax protective antigen-directed antibody interactions [moa]. Approved for anthrax protective antigen-directed antibody [epc]. First approved in 2012.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Raxibacumab is a monoclonal antibody that binds to anthrax protective antigen, neutralizing the toxin produced by Bacillus anthracis. It is indicated for inhalation anthrax and bacterial infections caused by anthrax. The drug works by blocking the interaction between protective antigen and anthrax toxin, preventing cellular entry and toxin-mediated damage.
Peak
Product remains in peak lifecycle phase with limited public spending data; team size likely stable but specialized due to niche biodefense indication.
Mechanism of Action
Anthrax Protective Antigen-directed Antibody Interactions
Pharmacologic Class:
Anthrax Protective Antigen-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax
Started May 2027
10 enrolled
Infections, Bacterial
Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario
Started Jan 2027
100 enrolled
Infections, Bacterial
Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed
Started Feb 2015
573 enrolled
Infections, Bacterial
A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects
Started Mar 2008
322 enrolled
Healthy
An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection
Started Jan 2008
20 enrolled
Therapeutic Treatment of Inhalation Anthrax
Worked on RAXIBACUMAB at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.